Bayer AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bayer AG with three other
pharmaceutical manufacturers in Europe:
sales of 48.88 billion Swiss Francs [US$50.28 billion]
of which 66%
was innovative medicines),
(34.71 billion Euro [US$38.91 billion]
of which 84%
was Pharmaceuticals), and
Roche Holding Aktiengesellschaft
based in Switzerland
(50.58 billion Swiss Francs [US$52.03 billion]
of which 77%
Bayer AG reported sales of 46.77 billion Euro (US$52.43 billion)
December of 2016.
a very small
increase of 1.0%
versus 2015, when the company's sales were 46.32 billion Euro.
Sales at Bayer AG have increased during each of the previous five years
(and since 2011, sales have increased a total of 28%).
Sales of Reconciliations saw an increase
that was more than double the company's growth rate: sales were up
50.0% in 2016, from
4.00 million Euro to 6.00 million Euro.
Bayer AG also saw significant increases in sales in
Pharmaceuticals and Biological Products (up 19.5% to 16.42 billion Euro)
Not all segments of Bayer AG experienced an increase in sales in 2016:
sales of Consumer Care fell 33.9% to 6.04 billion Euro.
Bayer AG also experienced decreases in sales in
Cropscience (down 4.4% to 9.92 billion Euro)
All Other Segments (down 5.0% to 1.04 billion Euro)